Abstract
Lyzed epimastigotes of Trypanosoma cruzi clones P209-1, Gamba1, Sp104-1, MASu, Y7/1, MN12, Cl-Brener, 86/2036, Y7/2-1 inhibit the growth of Ehrlich adenocarcinoma in mice. The tumor decreased 1.5–3 times after 12 daily injections of lysates from 15 million epimastigotes. The protective effect progressed after the injections were discontinued and depended on the dose and lysate producer clone. Trypanosoma lysates in the studied doses were nontoxic.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
V. D. Kallinikova, Antitumor Characteristics of T. cruzi, a Flagellar Protozoon [in Russian], Moscow (2004).
Yu. S. Korshunov, I. A. Osmanov, V. D. Kallinikova, et al., Vestn. Rossiisk. Univers. Druzhby Narodov, No. 1, 77–80 (2005).
L. A. Sheklakova, V. D. Kallinikova, and L. P. Karpenko, Byull. Eksp. Biol. Med., 135, No. 1, 103–106 (2003).
L. A. Sheklakova, V. D. Kallinikova, L. P. Karpenko, and M. Tibayrinc, Biomed. Tekhnol., No. 16, 224–230 (2001).
Author information
Authors and Affiliations
Additional information
__________
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 142, No. 10, pp. 454–457, October, 2006
Rights and permissions
About this article
Cite this article
Batmonkh, Z., Kallinikova, V.D., Pakhorukova, L.V. et al. In vivo anticancer activity of lysates from Trypanosoma cruzi of different genetic groups. Bull Exp Biol Med 142, 470–473 (2006). https://doi.org/10.1007/s10517-006-0395-6
Received:
Issue Date:
DOI: https://doi.org/10.1007/s10517-006-0395-6